QUOTE AND NEWS
Motley Fool  Dec 4  Comment 
What if everything went perfectly right for the biotech?
Motley Fool  Dec 3  Comment 
Dendreon's fall from grace wasn't pretty, and another once highly regarded biotech may eventually follow suit.
SeekingAlpha  Nov 11  Comment 
Benzinga  Nov 10  Comment 
Dendreon Corporation (NASDAQ: DNDN) warned Monday that shareholders could be out of luck. The Seattle-based maker of Provenge, once hailed as a potential blockbuster drug for prostate cancer, filed for Chapter 11 bankruptcy Monday, sending...
MarketWatch  Nov 10  Comment 
Merck & Co. and Dendreon miss out on a health-care sector rally.
Benzinga  Nov 10  Comment 
Dendreon (NASDAQ: DNDN) shares dipped 65.71% to $0.32 on Chapter 11 filing. Rayonier (NYSE: RYN) shares dropped 13.50% to $29.32. Rayonier reported better-than-expected earnings for the third quarter. The company announced its plans to realign...
StreetInsider.com  Nov 10  Comment 
Dendreon (NASDAQ: DNDN) 69% LOWER ; and its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court) on November 10, 2014. iBio, Inc. (NYSE: IBIO)...
FiercePharma  Nov 10  Comment 
Struggling Dendreon has tried streamlining its manufacturing process for cancer vaccine Provenge. It's tried laying off hundreds of employees, cutting operating costs and raising capital. And it's tried putting itself up for sale. But no dice: The...
Benzinga  Nov 10  Comment 
Dendreon (NASDAQ: DNDN) shares slipped 67.09% to $0.31 in pre-market trading on Chapter 11 filing. Gogo (NASDAQ: GOGO) fell 9.80% to $15.01 in pre-market trading after the company reported a wider-than-expected Q3 loss. GoPro (NASDAQ: GPRO)...




 
TOP CONTRIBUTORS

Dendreon Corporation (NYSE:DNDN) is a biotechnology company with a focus on developing drugs for cancer. Its most advanced product is Provenge (Sipuleucel-T), approved by the FDA in 2010, is a therapeutic vaccine developed for the treatment of prostate cancer. Successful late-stage clinical trials yielded very positive results that could turn Provenge into a blockbuster therapy. Dendreon is beginning to market Provenge in the U.S. on its own.

Dendreon's success over the next few years will depend both on its ability to expand capacity to keep up with demand for the drug as well as overall success of Provenge in the advanced prostate cancer market.

Business Growth

FY 2010 (ended December 31, 2010

  • Net revenue surpassed $1 million for the first time at $48 million.[1]
  • Revenue forecast for 2011 is$350 to 400 million.[2]

In 2010, Dendreon achieved FDA approval for its flagship therapy, Provenge, to treat advanced prostate cancer.[3] Revenue from sales of Provenge drove Dendreon's revenue increase in 2010, and will continue to drive Dendreon's revenue as it continues to build market share. Dendreon has yet to post a profit, and operational expenses to develop, manufacture, and market Provenge tripled to $300 million in 2010. Thomson Reuters projects an earnings loss again in 2011, but sees Dendreon becoming profitable in 2012.[4]

Pipeline

Provenge treats cancer as an active cellular immunotherapy (ACI), getting the patient's immune system to selectively attack cancer cells. Dendreon is developing the Provenge compound (Sepuleucel-T) as well as other ACI compounds for several cancer types[5]:

  • Sepuleucel-T: Dendreon currently has Sepuleucel-T, the compound behind Provenge, in Phase 2 and 3 trials for both early and advance stage Prostate cancer.
  • ACI Therapy for Breast Cancer: Dendron has a therapy that targets the Her2 receptor common in certain forms of breast cancer currently in Phase 1 trials.

Trends and Forces

Sales Growth for Provenge Will Drive Dendreon's Future Revenue

Over the next few years, virtually all of Dendreon's revenue will come from sales of its cancer drug, Provenge. Analysts predict that Provenge sales will peak at $2-3 billion, with sales in 2012 of $800 million.[6] However, the sales numbers that Dendreon is actually able to realize depend on a few factors. First, as the first cancer treatment of its kind, demand for Provenge may be difficult to predict. Second, Provenge costs $93,000 for 4 months of life extension in cancer patients, a cost that some doctors may balk at.[7] Dendreon's valuation over the next few years will be inextricably tied to the performance of Provenge.

Dendreon's Ability to Keep Up with Provenge Demand will Affect Revenue

The process of manufacturing Provenge is relatively complex, requiring treatments personalized for each patient, and Dendron may have trouble keeping up with demand. Early on, the company has seen production constraints dampen sales.[8][9] While Dendreon has added three manufacturing plants to its arsenal in order to meet demand,[10] the complexities inherent to the manufacturing process make manufacturing capacity an important indicator for Provenge's short-term sales.

Competition

Sanofi-Aventis SA (SNY): Sanofi Aventis received FDA approval for it new drug, Jevtana, to treat patients with advanced prostate cancer. Jevtana will compete with Provenge for patients, although the demand backlog for Provenge while Dendreon ramps up its capacity, will make up for any sales losses from competition.[11]

JOHNSON & JOHNSON (JNJ): Zytiga received FDA approval for advanced prostate cancer and will compete along with Provenge and Jevtana for market share.[12]

References

  1. DNDN 2011 10K
  2. BiotechSectorInvesting DNDN Earnings
  3. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer
  4. Ahead of Earnings: Analysts Fight Over Dendreon (DNDN)
  5. Dendreon R&D
  6. Dendreon: Make or Break Year for Provenge
  7. Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?
  8. Dendreon's Biggest Provenge Problem? Managing Demand
  9. Dendreon sees Provenge contraints over by year end
  10. Dendreon boosts Provenge production, treatment sites
  11. New Dendreon Competition Is Not Really Competition (DNDN, SNY)
  12. Abiraterone in Prostate Cancer, Survival Gets Even Better
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki